Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.48 |
| ▸ | ELANE | P08246 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25548856 | 0.91 | ELANE (0.55) | PTPN1GPR132ELANEPPARGCXCR2 | |
| SCHEMBL25194649 | 0.87 | PTPN1 (0.57) | PTPN1GPR132ELANEPPARGMEN1 | |
| SCHEMBL25194648 | 0.87 | PTPN1 (0.57) | PTPN1GPR132ELANEPPARGMEN1 | |
| SCHEMBL23460860 | 0.87 | ELANE (0.50) | PTPN1GPR132ELANEPPARGCXCR2 | |
| SCHEMBL23461004 | 0.87 | GPR34 (0.56) | GPR132ELANEPPARGCXCR2LMNA | |
| SCHEMBL23460863 | 0.87 | ELANE (0.50) | PTPN1GPR132ELANEPPARGCXCR2 | |
| SCHEMBL23461000 | 0.87 | GPR34 (0.56) | GPR132ELANEPPARGCXCR2LMNA | |
| SCHEMBL23460938 | 0.86 | CXCR2 (0.52) | PTPN1GPR132ELANEPPARGCXCR2 | |
| SCHEMBL23460942 | 0.86 | CXCR2 (0.52) | PTPN1GPR132ELANEPPARGCXCR2 | |
| SCHEMBL23461061 | 0.85 | CXCR2 (0.61) | PTPN1GPR132ELANEPPARGCXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | PTPN1 1876/4885GPR132 750/4885ELANE 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.